Access to definitive treatment and survival for intermediate-risk and high-risk prostate cancer at hospital systems serving health disparity populations.
Nguyen DD, Labban M, Briggs L, Wallis CJD, Cole AP, Lipsitz SR, Iyer HS, Rebbeck TR, Weissman JS, Choueiri TK, Trinh QD.
Urol Oncol. 2023 Feb 07. PMID: 36759298